Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab in Metastatic Anal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02919969
Recruitment Status : Recruiting
First Posted : September 30, 2016
Last Update Posted : May 14, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
James Cleary, MD, PhD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2023